Literature DB >> 17034609

Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis.

Xiongbing Zu1, Zhengyan Tang, Yuan Li, Ning Gao, Jian Ding, Lin Qi.   

Abstract

OBJECTIVE: To elucidate the role of vascular endothelial growth factor-C (VEGF-C) in bladder transitional cell carcinoma (TCC), examining VEGF-C expression in bladder TCC tissue and the association of VEGF-C with clinicopathological features, as the expression of VEGF-C in several carcinomas is significantly associated with angiogenesis, lymphangiogenesis and regional lymph node metastasis, but there are few reports of VEGF-C expression in bladder TCC. PATIENTS AND METHODS: The study included 45 patients with bladder TCC; VEGF-C expression was assessed by immunohistochemistry and the association between VEGF-C expression and angiogenesis, as evaluated by microvessel density (MVD), was examined.
RESULTS: There was VEGF-C expression in the cytoplasm of tumour cells, but very little in the normal transitional epithelium. VEGF-C expression was significantly associated with tumour size, pathological T stage, pathological grade, lymphatic-venous involvement and pelvic lymph node metastasis (all P < 0.05). Multivariate analysis showed that VEGF-C expression was an exclusive independent factor influencing pelvic lymph node metastasis. Moreover, the patients with high VEGF-C expression had a markedly poorer prognosis than those with no or low VEGF-C expression (P = 0.014). A multivariate analysis based on the Cox proportional hazard model showed that lymph node metastasis was only an independent prognostic factor in the multivariate analysis using the Cox regression model (P = 0.010).
CONCLUSION: The present study provides evidence supporting the involvement of VEGF-C expression in the promotion of lymph node metastasis in bladder TCC. Examination of VEGF-C expression in biopsy specimens might be beneficial in predicting pelvic lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034609     DOI: 10.1111/j.1464-410X.2006.06446.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  24 in total

Review 1.  Biomolecular predictors of urothelial cancer behavior and treatment outcomes.

Authors:  Michael Rink; Eugene K Cha; David Green; Jens Hansen; Brian D Robinson; Yair Lotan; Arthur I Sagalowsky; Felix K Chun; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

2.  EGFR, CD10 and proliferation marker Ki67 expression in ameloblastoma: possible role in local recurrence.

Authors:  Azza Abdel-Aziz; Maha M Amin
Journal:  Diagn Pathol       Date:  2012-02-02       Impact factor: 2.644

3.  [Lymphangiogenesis axis in bladder carcinoma. An analysis with tissue microarray technology].

Authors:  E Herrmann; E Eltze; S Bierer; L Hertle; C Wülfing
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  miR-128 downregulation promotes growth and metastasis of bladder cancer cells and involves VEGF-C upregulation.

Authors:  X U Zhou; Lin Qi; Shiyu Tong; Y U Cui; Jinbo Chen; Tianxiang Huang; Zhi Chen; Xiong-Bing Zu
Journal:  Oncol Lett       Date:  2015-09-09       Impact factor: 2.967

5.  siRNA-mediated knockdown of VEGF-A, VEGF-C and VEGFR-3 suppresses the growth and metastasis of mouse bladder carcinoma in vivo.

Authors:  Feng Wang; Hui-Ming Li; Hui-Ping Wang; Jia-Lie Ma; Xia-Fang Chen; Fang Wei; Miao-Ying Yi; Qian Huang
Journal:  Exp Ther Med       Date:  2010-07-12       Impact factor: 2.447

6.  MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer.

Authors:  Hiroshi Hirata; Yuji Hinoda; Koji Ueno; Varahram Shahryari; Z Laura Tabatabai; Rajvir Dahiya
Journal:  Carcinogenesis       Date:  2011-11-01       Impact factor: 4.944

7.  Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer.

Authors:  Changhao Chen; Yuming Luo; Wang He; Yue Zhao; Yao Kong; Hongwei Liu; Guangzheng Zhong; Yuting Li; Jun Li; Jian Huang; Rufu Chen; Tianxin Lin
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 8.  Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand?

Authors:  Samir P Shirodkar; Vinata B Lokeshwar
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

Review 9.  Growth factors and receptors as prognostic markers in urothelial carcinoma.

Authors:  Peter C Black; Colin P N Dinney
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

10.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.